InterAx Biotech’s Post

🎉Ecstatic to unveil our latest breakthrough! 'The Tumor Microenvironment: Shaping Cancer Progression and Treatment Responses' in the esteemed Taylor and Francis Journal of Chemotherapy. This achievement signifies a substantial advancement in our comprehension of cancer and its therapeutic approaches. I extend my sincere congratulations to our esteemed guide, Dr. Sharav Desai and Dr. Vipul P. Patel, for their invaluable guidance, and profound appreciation to our diligent team members, Kirti Thombare and Sandip Nagare, for their unwavering dedication to this pursuit at Sanjivani Group of Institutes, specifically SRES' Sanjivani College of Pharmaceutical Education and Research,Kopargaon. Dive into our paper with the DOI: https://lnkd.in/dsbQeGgJ #cancerresearch #tumormicroenvironment #cytokines #chemotherapy #immunotherapy

The multiple myeloma treatment landscape is rapidly evolving with groundbreaking advancements! In 2023, there were around 75,000 incidence cases in the 7MM, predominantly affecting those aged 65+. Key therapies include Proteasome Inhibitors like VELCADE, KYPROLIS, and NINLARO; IMiDs such as THALOMID, REVLIMID, and POMALYST; Monoclonal Antibodies like DARZALEX and SARCLISA; CAR-T Cell Therapies such as ABECMA and CARVYKTI; and Bispecific Antibodies like TALVEY. The market, valued at approximately $21.3B, is driven by innovators like GSK, Bristol Myers Squibb, AbbVie, and Janssen Inc.. Learn more about the latest breakthroughs and market dynamics here: https://lnkd.in/gQmc-CXc #MultipleMyeloma #CancerResearch #PharmaInnovation #Healthcare #Biotech #MedicalAdvancements

Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C #G12D

#CAR_T_Cell_Therapy Market Size, Trends, Growth Rate, Analysis Report Upto 2032 >> https://lnkd.in/dvunEJHN #CAR T cell therapy is an advanced form of #immunotherapy that involves modifying a #patient’s T cells to target and attack #cancer cells. This therapy uses genetically engineered T #cells with chimeric antigen #receptors (CARs) that bind to cancer cell #antigens. These therapies provide a highly targeted and personalized #treatment approach by enhancing the T cells' ability to recognize and #destroy malignant cells. Gilead Sciences Novartis Bristol-Myers Squibb Pharma Company Janssen Global Services LLC Caribou Biosciences JW Therapeutics 药明巨诺 Cartesian Therapeutics Aurora BioPharma #celltherapy #immunotherapy #cancercells #therapies #treatment #research #bloodcancers #leukemia 

📢 Register your place on our upcoming webinar! Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology. 👉 Review key cytokines involved in inflammatory diseases 👉 Examine case studies highlighting the application of various cell-based assay formats to assess the mechanism of action of antibodies targeting existing & emerging cytokine targets in inflammatory disease 👉 Understand optimal assay formats for assessing antibody specificity vs successful detection of neutralizing antibodies in cell-based assays Interested? Sign up here: https://bit.ly/3vpPZoi #Webinar #Assays #Therapeutics #Cytokines

If you focus on oncology research and need data analysis for: 🔵 Drug target identification and validation 🔵 Biomarker identification for mechanism of action or drug efficacy 🔵 Biomarker prediction for patient stratification We can help! ⬇️Check the link in our comment below to discover our oncology services!⬇️

Interested in KRAS? Tempus is presenting Beyond G12: Comprehensive RAS Biomarker Strategy and Clinical Development at RAS-Targeted Drug Development Summit 2024 KRAS G12C is only the first druggable alteration in RAS genes. Tempus’ multimodal, de-identified data and certain assays can help identify a broad set of biomarkers in responsive patients including KRAS, HRAS, and NRAS amplifications, over-expression, and mutations, in addition to tumor immune microenvironment factors that may influence response to RAS neoantigen vaccines, revealing critical insights for targeted therapy development. Gain perspective on the significance of RAS alteration patterns to outcomes to standard of care and their potential to guide precision oncology, enhancing treatment efficacy and patient outcomes. Not attending? Let's connect! #PrecisionOncology #ClinicalDevelopment #BiomarkerStrategy #RAS #KRAS #NRAS #G12C

To effectively optimize drug dosage in early phase oncology, sponsors should plan for added operational load from increased data collection, assessments and strict turnaround time for assay work. In this Contract Pharma article, IQVIA Biotech’s VP of Immuno-Oncology & CAGT Erin Finot, MS, MBA discusses operational considerations for clinical trial stakeholders. Read the article to learn more. https://bit.ly/3UdblQ0 #IQVIABiotech #clinicaltrials #oncology

The rapid advancement of targeted therapeutics has significantly improved treatment precision and efficacy in oncology and metabolic disorders. This article integrates key developments in four areas: highly selective PPAR modulators for metabolic and inflammatory diseases; CRISPR-engineered T-cell receptor therapies targeting the KRAS G12D mutation in cancer; strategies to enhance antitumor immunity through glutamine metabolism modulation in the tumor microenvironment; and a novel system for analyzing coformulated biologics. These innovations highlight the integration of metabolic modulation, immune system engineering, and advanced biologic formulation, paving the way for more effective and personalized therapeutic approaches. #drugdevelopment #science #medicinalchemistry #drugdiscovery #medicine #drugspharmaceuticals #oncology #drug - https://lnkd.in/gpEh-snJ